Clinical Trials
12 trialsNCT07560826 2026-05-01
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Wake Forest University Health Sciences
Phase 2 Not yet recruiting
NCT07514819 2026-04-23
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
St. Jude Children's Research Hospital
Phase NA Not yet recruiting
NCT07516353 2026-04-08
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Dana-Farber Cancer Institute
Phase NA Not yet recruiting
NCT07444918 2026-03-03
Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07211737 2026-02-06
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07142863 2025-08-27
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06726512 2024-12-10
qMAP
University Medical Center Groningen
Phase NA Not yet recruiting
NCT06699576 2024-11-21
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Hansoh BioMedical R&D Company
Phase 1 Not yet recruiting
NCT06524778 2024-08-07
Single High-dose Brachytherapy for Giant Osteosarcoma Masses
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 2 Not yet recruiting
NCT06412458 2024-05-14
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06041490 2023-09-18
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05590572 2022-10-21
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Not yet recruiting